Study reveals GLP-1s could reduce risk of cancer in patients with type 2 diabetes
10 Jul 2024
Preview
Source: PMLiVE
A new study conducted by researchers at Case Western Reserve University School of Medicine, Ohio, has revealed that patients living with type 2 diabetes (T2D) treated with semaglutide are less likely to develop certain cancers.
The research published in JAMA Network Open revealed that patients taking semaglutide, marketed under brand names including Ozempic and Wegovy, or glucagon-like peptide-1 receptor antagonists (GLP-1 RAs) had a decreased risk of developing ten of the 13 obesity-linked cancers, including gallbladder and kidney cancer.
Researchers analysed the medical records of 1.6 million T2D patients who were either on GLP-1 medicines, insulin or metmorfim between March 2005 and November 2018, who had no previous history of obesity-related cancers.
The team found that patients who received GLP-1 treatment had significantly reduced risks of certain cancers, including gallbladder cancer by 65%, meningioma (63%), pancreatic cancer (59%), hepatocellular carcinoma (53%), ovarian cancer (48%), and more.
However, semaglutide was not linked to a significantly reduced risk of developing thyroid, stomach or breast cancer, and the team found no significant decrease in cancer risk associated with GLP-1 RAs when compared with metformin.
Yoni Resnick, director of pharmacy clinical services, New England Cancer Specialists, said: “By offering this type of weight reduction medication as compared to other types of medications… you’re reducing the risk for cancer, thus improving the overall health of the population [and] cutting healthcare costs.”
Researchers intend to conduct more research, including pre-clinical and clinical trials, to build on these findings.
As well as cancer, diabetes drugs have also demonstrated benefits in reducing the risk of major adverse cardiovascular events (MACE) in patients with T2D, including stroke and heart disease.
In 2020, new labelling for Novo Nordisk’s Ozempic (semaglutide) was approved by the US Food and Drug Administration to indicate that it could reduce the risk of MACE in T2D patients with heart disease.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.